Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

BACKGROUND: For patients with acute myeloid leukaemia (AML), the only potentially curative treatment is intensive chemotherapy (IC). This is highly toxic, particularly for patients > 60 years, potentially leading to prolonged hospitalisations requiring intensive supportive care, and sometimes tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dillon, Richard, Maycock, Shanna, Jackson, Aimee, Fox, Sonia, Freeman, Sylvie, Craddock, Charles, Thomas, Catherine, Homer, Emma, Leahy, Jane, Mamwell, Anna, Potter, Nicola, Russell, Nigel, Wei, Andrew, Ommen, Hans Beier, Hemmaway, Claire, Knapper, Steve, Billingham, Lucinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664612/
https://www.ncbi.nlm.nih.gov/pubmed/36376888
http://dx.doi.org/10.1186/s12885-022-10221-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664612/
https://www.ncbi.nlm.nih.gov/pubmed/36376888
http://dx.doi.org/10.1186/s12885-022-10221-2

Ejemplares similares